4月17日，据CDE官网消息，江西银涛药业股份有限公司联合申请药品“反流清颗粒”，获得临床试验默示许可，受理号CXZL2500005。
公示信息显示，药品“反流清颗粒”适应症：慢性非萎缩性胃炎伴胆汁反流中医辨证属脾胃湿热证。
江西银涛药业股份有限公司，成立于2001年，位于抚州市，是一家以从事医药制造业为主的企业。企业注册资本5509.764万人民币，实缴资本5509.764万人民币。
通过天眼查大数据分析，江西银涛药业股份有限公司共对外投资了6家企业，参与招投标项目5000次，知识产权方面有商标信息23条，专利信息79条，此外企业还拥有行政许可19个。
主要股东信息显示，江西银涛药业股份有限公司由张建荣持股52.416%、抚州市临川区益顺佳投资中心（有限合伙）持股38.4408%、南丰县德源管理咨询合伙企业（有限合伙）持股2.3607%、南丰县亮达管理咨询中心（有限合伙）持股1.6981%、黄亮持股1.3701%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.